Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

There is limited evidence regarding early treatment of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to mitigate symptom progression.

Who Took Part

The study group was 214 patients.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

This multicenter, single health system randomized clinical factorial open-label trial enrolled 214 adult patients with a diagnosis of SARS-CoV-2 infection confirmed with a polymerase chain reaction assay who received outpatient care in sites in Ohio and Florida.

How the Study Was Run

In design terms this was a randomized, open-label and multicenter study.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Being open-label, the Vitamin D, K2, Magnesium and Zinc study did not mask who received what.

More than one site took part, so the patients came from several places.

The trial was conducted from April 27, 2020, to October 14, 2020.

What Was Measured

The subject headings attached to it are Ambulatory Care, Antioxidants, Ascorbic Acid, COVID-19, Cough, Dietary Supplements and Dyspnea.

What This Means in Plain Language

The paper is a randomized, open-label and multicenter study of Vitamin D, K2, Magnesium and Zinc in 214 patients.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (JAMA network open), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.